Reata Sets Sights On 2012 Bardoxolone Launch With $78 Million Financing In Hand
This article was originally published in The Pink Sheet Daily
Executive Summary
Funding will allow Reata to complete the second of two pivotal trials for its lead product candidate in development for advanced chronic kidney disease.